User login

Enter your username and password here in order to log in on the website:
Choose language: English | Deutsch

Infront up-to-date–
news, dates, events



Webinar: Customer Account | Postbox, Portfolio Access
Product training

We cordially invite you to the webinar "Customer Account | Postbox, Portfolio Access" on Tuesday, October 06, 2020 from 11:00 to 12:00. The event will be held in German language, please contact us, if you’re interested in an English version.

Customer Account is the digital solution for your customers:

  •     Postbox | Provision of digital documents: reports, news, advertising
  •     Portfolio Access | Display of portfolio information: Assets, performance, risks, realized gains and losses, earnings, transactions and forecasts on an individual security and portfolio basis

An introduction is followed by live demonstrations and an overview of all available variants including a sneak preview of further development. Afterwards, we will of course be available to answer your questions.

Here you can register for the free webinar.

11th AM Tech Day
Exhibitions and Congresses

AM TECH DAY is the European market event dedicated to the impact of technological innovation on the asset management industry, gathering asset managers, wealth managers, asset owners, insurers and FinTechs. For its 11th year, the event will be held on 13 October at the Palais Brongniart, Paris.

The health crisis has made it more vital than ever to communicate, talk and work online, effectively boosting the value of all tools that can do this in a fast and secure way. It has also spurred their adoption throughout the asset management industry with the early adopters effectively providing a stress test for the sector.

At the same time, technologies continue to improve, giving professional investors a better handle on the key issues affecting sustainable development and helping them adopt best practice in transparency, equity and security.

Now more than ever, the asset management industry has the means and the opportunity to reinvent itself.

Meet Infront there: Palais Brongniart, 16 Place de la Bourse, at 10:00.

19th COPS Usertreff
Exhibitions and Congresses

As in previous years, COPS invites to their annual COPS user meeting this year from 24 to 25 June 2021 at the Seehotel Rust in Rust on Neusiedlersee.

The customers can expect a versatile and varied program, ranging from innovations in software solutions, successful project reports to practical application examples.

As a strategic partner, COPS gives us the opportunity to present our company and our solutions and show-case the cooperation with COPS.

On site, our colleagues Catherine Hanek, Achim Beisswenger and Sebastian Ullrich will be available for a lively exchange of ideas.

You can find further information here...

SIPUGday 2020
Exhibitions and Congresses

The SIPUGday focuses since the start on market data and related technologies, services and products in the front, back and middle office. Regulations and their impact on data are also a topic for our audience.

Infront and vwd will be represented on site by Ivo Bieri, Managing Director Switzerland. He will be happy to inform you about the advantages for you of the merger of the two companies in the future. We look forward to a lively exchange with you!

October 27, 2020

Marriott Hotel,
Neumühlequai 42
8006 Zurich


Quantalys Inside 2020
Exhibitions and Congresses

Further information will be available shortly here or under Quantalys Inside 2020.

DKF 2021, 10. D-A-CH Kongress für Finanzinformationen
Exhibitions and Congresses

We will again be represented at the DKF this year and look forward to your visit to our stand.

Further information will be available here soon or on the official DKF 2021 website.

 Latest news on markets, economy and companies


Business Wire



13.08.2020 GlobeNewswire: Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020

Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020


Allschwil, Switzerland – August 13, 2020



Idorsia Ltd (SIX: IDIA) today announced that the positive results from the

first pivotal Phase 3 study investigating 25 and 50 mg doses of its dual orexin

receptor antagonist, daridorexant, in adult and elderly patients with insomnia,

are to be presented at SLEEP 2020 . Due to the COVID-19 pandemic, the

Associated Professional Sleep Societies (APSS) is turning SLEEP 2020, the

world’s largest meeting devoted entirely to clinical sleep medicine, and sleep

and circadian research, into a virtual meeting from August 27 – 30, 2020. The

meeting has live-streamed content as well as on-demand recorded sessions to



The abstract entitled “A Phase 3, Multi-Center, Double-Blind, Randomized,

Placebo-Controlled, Polysomnography Study to Assess Efficacy and Safety of

Daridorexant in Adult and Elderly Insomnia Patients” will be presented as an

oral presentation by Dr Thomas Roth, PhD, Director of the Sleep Disorder and

Research Center at Henry Ford Hospital, and will be available on demand to

registered attendees of SLEEP 2020 as part of the late-breaking program.


More information and the late breaking abstract is available in the Virtual

Sleep 2020 meeting guide .


The Phase 3 program design will also be presented as a poster entitled “0521 –

Daridorexant (ACT-541468), a dual orexin receptor antagonist for the treatment

of insomnia disorder: double blind, randomized, Phase 3 studies for efficacy

and safety in adult and elderly patients”. The poster will be available on

demand to registered attendees of SLEEP 2020 and the abstract can be found in

the Abstract Supplement .


In April and July 2020, Idorsia reported positive results in each of the two

pivotal Phase 3 studies of daridorexant in patients with insomnia. More details

and commentary can be found in the dedicated press releases ( first study

release ), ( second study release ) and the investor webcasts ( first study

webcast ), ( second study webcast ) which are available for replay on the

corporate website.




Notes to the editor


About the Phase 3 registration program

The Phase 3 registration program comprises two confirmatory studies of 3-month

duration, together with a long-term extension study. Both pivotal studies are

complete, having enrolled around 1,850 patients with insomnia at over 160 sites

across 18 countries. As insomnia often presents later in life, around 40% of

the recruited population was aged 65 years or older. The confirmatory

multi-center, double-blind, randomized, placebo-controlled, parallel-group,

polysomnography studies investigated three doses of daridorexant (10 mg, 25 mg,

and 50 mg) on sleep and daytime functioning parameters, objectively in a sleep

lab by polysomnography and subjectively with a daily patient diary at home.


The impact of insomnia on patients’ daytime functioning was measured daily

using the sleepiness domain score from the Insomnia Daytime Symptoms and

Impacts Questionnaire (IDSIQ) a Patient Reported Outcome (PRO) instrument,

validated according to the US Food and Drug Administration (FDA) Guidance for

Industry. 806 patients decided to continue treatment in the ongoing 40-week

extension study which will measure the effect of all three doses vs. placebo,

generating data for long-term treatment of insomnia.



About insomnia

Insomnia is defined as a combination of dissatisfaction with sleep and a

significant negative impact on daytime performance. Dissatisfaction with sleep

refers to the difficulty to initiate and/or maintain sleep on at least three

nights per week for at least three months, despite adequate opportunity to



Insomnia is, worldwide, the most commonly reported sleep disorder and its

impact is often underestimated. In reality, it can be a distressing condition

that can impair quality of life. Sleepless nights can leave people feeling

irritable and out of sorts – this may affect many aspects of daily life, from

studying and employment to social activities and relationships. People who

suffer from insomnia may lack the energy or motivation to exercise or to take

part in social activities. It can also have a significant economic impact as it

increases the risk of accident and injury on the road or in the workplace, and

is a leading cause of absenteeism and reduced productivity at work. People with

insomnia are more likely to experience feeling down or depressed, lack

concentration, and suffer from poor energy levels during the day compared with

people who sleep well. In addition, worrying about sleep can cause stress and

may lead to negative thought patterns which may in turn make it more difficult

to sleep, setting up a vicious cycle. Chronic insomnia is associated with

cardiovascular and cerebrovascular diseases, and increased mortality.


The goal of treatment for insomnia is to improve sleep quality and quantity,

as well as to reduce insomnia-related impaired daytime performance, while

avoiding adverse events and next morning residual effects. Current treatment of

insomnia includes cognitive behavioral therapy, sleep hygiene recommendations,

and pharmacotherapy. The most widely prescribed products on the market that are

indicated for insomnia enhance the effects of gamma-aminobutyric acid (GABA),

the major inhibitory neurotransmitter in the central nervous system. Such

medications are only approved for short-term use and are associated with side

effects such as next-day effects, anterograde amnesia, and risk of tolerance

and dependence.


About Dr. Thomas Roth, PhD

Dr. Roth has been the Director of the Sleep Disorders and Research Center at

Henry Ford Hospital in Detroit, since 1978. Dr. Roth is also a Professor in the

Department of Psychiatry at Wayne State University, School of Medicine in

Detroit, Michigan, and serves as a Clinical Professor in the Department of

Psychiatry at the University of Michigan, College of Medicine in Ann Arbor.


After serving as president of the Sleep Research Society, and the founding

president of the National Sleep Foundation (NSF), Dr. Roth became chairman of

the National Center on Sleep Disorders Research advisory board. In addition, he

was a member of the board of directors of the Associated Professional Sleep

Societies (APSS), chaired the Association's Scientific Program Committee and

the governing board of the World Federation of Sleep Research Societies.


Dr. Roth was instrumental in the formation of the Association of Sleep

Disorders Center (ASDC) and served as the organization's second president. He

is also the former Chairman of the World Health Organization's worldwide

project on sleep and health. In addition to authoring and co-authoring numerous

articles, Dr. Roth serves as past editor-in-chief of the journal Sleep. He

currently sits on the editorial boards of Sleep Reviews, Stress Medicine, and

Advances in Therapy and Human Psychopharmacology.


In 2002, Dr. Roth received the NSF's Lifetime Achievement Award for his

accomplishments and contributions to sleep science, sleep medicine and public

health. He received a Distinguished Research Award from the Sleep Research

Society as well as the Nathanial Kleitman Award from the Academy of Sleep

Medicine. Dr. Roth's contributions to the sleep field are expansive, ranging

from prolific research productivity and scholarship to multiple national

leadership positions, as well as the mentoring of many students and colleagues.

Dr. Roth serves as a consultant to Idorsia.


About Idorsia

Idorsia Ltd is reaching out for more - We have more ideas, we see more

opportunities and we want to help more patients. In order to achieve this, we

will develop Idorsia into one of Europe’s leading biopharmaceutical companies,

with a strong scientific core.


Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is

specialized in the discovery and development of small molecules, to transform

the horizon of therapeutic options. Idorsia has a broad portfolio of innovative

drugs in the pipeline, an experienced team, a fully-functional research center,

and a strong balance sheet – the ideal constellation to bringing R&D efforts to

business success.


Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June

2017 and has over 800 highly qualified specialists dedicated to realizing our

ambitious targets.


For further information, please contact

Andrew C. Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil

+41 58 844 10 10


The above information contains certain 'forward-looking statements', relating

to the company's business, which can be identified by the use of

forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',

'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',

'pending' or 'anticipates' or similar expressions, or by discussions of

strategy, plans or intentions. Such statements include descriptions of the

company's investment and research and development programs and anticipated

expenditures in connection therewith, descriptions of new products expected to

be introduced by the company and anticipated customer demand for such products

and products in the company's existing portfolio. Such statements reflect the

current views of the company with respect to future events and are subject to

certain risks, uncertainties and assumptions. Many factors could cause the

actual results, performance or achievements of the company to be materially

different from any future results, performances or achievements that may be

expressed or implied by such forward-looking statements. Should one or more of

these risks or uncertainties materialize, or should underlying assumptions

prove incorrect, actual results may vary materially from those described herein

as anticipated, believed, estimated or expected.




Anhang Medienmitteilung PDF



Subscribe to our free newsletter and you will receive the latest information about our products and solutions.